Innovation in the Biopharmaceutical Pipeline: A Multidimensional View

From Analysys Group

The U.S. innovative biopharmaceutical industry leads the world in the development of new medicines: over the past decade some 300 new
prescription medicines have been approved for use by the U.S. Food and Drug Administration (FDA). Together, these innovations have contributed to a range of new treatments resulting in improvements in the length and quality of life and reduced disease burden for
individuals and society. However, the need for innovative new therapies for some of the most costly and challenging diseases and conditions
has never been greater.

This study presents data on two types of potential new treatments in the research and development pipeline:

  • New medicines in development, or new molecular entities (NMEs) – data for which are referred to in this report as new “products”; and
  • New molecule-indication combinations in development (which may be NMEs or new indications for medicines previously approved by the
    FDA) – data for these unique molecule-indication combinations are referred to in this report as “projects.”

    • Download the white paper here.